G-MDSCs exert mild to no effect on attenuation of immune-mediated BMF in MHC-mismatched CByB6F1 recipients. (A) G-MDSC treatment of murine BMF in CByB6F1 model. BM G-MDSCs were isolated from CByB6F1 donor mice and were injected to MHC-mismatched CByB6F1 model at 10 × 106 G-MDSCs/mouse (BMF+Ly6G cell) at the time of B6 mice-derived LN cell infusion. (B) G-MDSCs from CByB6F1 donor mice (n = 14) did not improve pancytopenia and BM cellularity compared with control BMF mice (n = 12), even increased T-cell infiltration in BM. (C) BM G-MDSCs were isolated from B6 or BALB donor mice and were injected into MHC-mismatched CByB6F1 model at 10 × 106 G-MDSCs/mouse (BMF+Ly6G cells) at the time of B6-derived LN cell infusion. (D) B6-derived G-MDSCs (MHC-matched with B6 LN, n = 5) showed mild improvement of neutropenia and BM cellularity and decreased Fas expression in residual BM cells (RBM) in CByB6F1 recipient mice at day 14. BALB-derived G-MDSCs (MHC-mismatched with B6 LN, n = 6) did not show any improvement of BMF compared with control mice (n = 9). Data are shown as means with standard errors. ∗P < .05; ∗∗P < .01.
